# Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

> **NCT05222984** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **BIOLOGICAL:** Navitoclax
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05222984
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-29
- **Primary completion:** 2027-03-02
- **Final completion:** 2027-03-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222984, "Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05222984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*